Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1,” published in the March 2025 issue of ...